Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD’s 68Ga-Trivehexin (RAD301) featured in prestigious peer-reviewed journal RSC Medicinal Chemistry

Monday, December 18, 2023 1 min read
Key Takeaway: RAD's 68Ga-Trivehexin (RAD301) has been highlighted in the esteemed peer-reviewed journal RSC Medicinal Chemistry. This recognition is expected to bolster the visibility of RAD's research and may attract further interest from the scientific community. The publication underscores the significance of RAD301 in the field of medicinal chemistry.

Market Sentiment Analysis

POSITIVE FACTORS

  • 68Ga-Trivehexin (RAD301) featured in a prestigious journal.
  • Recognition in RSC Medicinal Chemistry enhances credibility.
  • Potential for increased visibility and interest in RAD's research.

Full Press Release Details

• Updates
• PDF
• December 18, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• March 7, 2025
• Updates
• January 5, 2024
• Announcements
• November 29, 2022
• Announcements
• March 23, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD301?

RAD301, also known as 68Ga-Trivehexin, is a therapeutic agent highlighted in recent research.

Where was RAD301 featured?

RAD301 was featured in the prestigious peer-reviewed journal RSC Medicinal Chemistry.

What is the significance of this publication?

The publication enhances RAD's visibility and credibility in the scientific community.

What does RAD301 target?

RAD301 is part of RAD's research in theranostics, focusing on targeted therapies.

Tags: RADX Viatris Investor Conferences Healthcare 68Ga-Trivehexin RSC Medicinal Chemistry peer-reviewed journal clinical research
Last updated: Dec 18, 2023